论文部分内容阅读
目的 研究CYFRA2 1 - 1在肺癌诊断、鉴别诊断中的临床应用价值。方法 应用酶联免疫法 (EIA)测定 1 1 0例健康人 ,92例非肿瘤肺疾病和 42 3例癌症患者 (其中包括 1 2 3例肺癌、97例肝癌、1 0 5例乳腺癌和 1 0 8例鼻咽癌 )血清中的CYFRA2 1 - 1的水平。结果 肺癌组CYFRA2 1 - 1的水平为 (8.2 4± 6 .72 ) μg/L明显高于健康对照组 (1 .67± 0 .68) μg/L及良性肺疾病组 (1 .92± 0 .95) μg/L ,差异均有高度显著性 (P <0 .0 0 1 )。以 >3 .3μg/L为阳性判断值 ,各组别阳性率分别为 :良性肺疾病组 5 .4 %、肺癌组 61 .0 %、乳腺癌组 2 6 .7%、肝癌组 2 3 .7%、鼻咽癌组 1 2 .0 %。经统计学分析 ,肺癌组其含量及阳性率与其他组别之间差异有显著性 (P <0 .0 5)。不同组织类型肺癌阳性率在 35 .7%～ 76 .1 %,其中以鳞癌为最高。结论 血清中CYFRA2 1 - 1的测定对肺癌的实验室诊断 ,尤其是鳞癌的诊断有重要的临床应用价值 ,它是敏感、特异性较高的肺癌肿瘤标志物。
Objective To investigate the clinical value of CYFRA2 1 - 1 in the diagnosis and differential diagnosis of lung cancer. Methods Totally 110 healthy subjects, 92 non-tumor lung diseases and 423 cancer patients (including 123 lung cancer, 97 hepatocellular carcinoma, 105 breast cancer and 1 cancer) were detected by enzyme-linked immunosorbent assay (EIA) 0 8 cases of nasopharyngeal carcinoma) serum levels of CYFRA2 1 - 1. Results The level of CYFRA2 1 - 1 in lung cancer group was (8.2 4 ± 6. 72) μg / L which was significantly higher than that in healthy control group (1.67 ± 0.68) μg / L and benign lung disease group (1.92 ± 0 .95) μg / L, the differences were highly significant (P <0.001). Positive rates of> 3. 3μg / L were positive in each group, respectively, which were 5.4% in benign lung disease group, 61.0% in lung cancer group, 26.7% in breast cancer group and 23.3% in hepatocellular carcinoma group. 7%, nasopharyngeal carcinoma group 12.0%. Statistically, there was a significant difference between the lung cancer group and other groups (P <0.05). The positive rates of lung cancer in different tissue types ranged from 35.7% to 76.1%, of which squamous cell carcinoma was the highest. Conclusion The determination of serum CYFRA2 1 - 1 in lung cancer laboratory diagnosis, especially in the diagnosis of squamous cell carcinoma has important clinical value, it is sensitive and specific high lung cancer tumor markers.